ATE225779T1 - Sulfonamidinhibitoren von matrix metalloproteinasen - Google Patents
Sulfonamidinhibitoren von matrix metalloproteinasenInfo
- Publication number
- ATE225779T1 ATE225779T1 AT96936718T AT96936718T ATE225779T1 AT E225779 T1 ATE225779 T1 AT E225779T1 AT 96936718 T AT96936718 T AT 96936718T AT 96936718 T AT96936718 T AT 96936718T AT E225779 T1 ATE225779 T1 AT E225779T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- date
- inhibitors
- matrix metalloproteinases
- gelatinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US737295P | 1995-11-17 | 1995-11-17 | |
PCT/US1996/016761 WO1997019068A1 (en) | 1995-11-17 | 1996-10-18 | Sulfonamide inhibitors of matrix metalloproteinases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE225779T1 true ATE225779T1 (de) | 2002-10-15 |
Family
ID=21725784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96936718T ATE225779T1 (de) | 1995-11-17 | 1996-10-18 | Sulfonamidinhibitoren von matrix metalloproteinasen |
Country Status (20)
Country | Link |
---|---|
US (3) | US5977141A (de) |
EP (1) | EP0874836B1 (de) |
JP (1) | JP2000514779A (de) |
AT (1) | ATE225779T1 (de) |
AU (1) | AU727569B2 (de) |
BG (1) | BG63967B1 (de) |
BR (1) | BR9611487A (de) |
CZ (1) | CZ291659B6 (de) |
DE (1) | DE69624262T2 (de) |
DK (1) | DK0874836T3 (de) |
ES (1) | ES2184893T3 (de) |
HU (1) | HUP9902083A3 (de) |
IL (1) | IL123901A (de) |
NO (1) | NO310231B1 (de) |
NZ (1) | NZ321293A (de) |
PL (1) | PL326700A1 (de) |
PT (1) | PT874836E (de) |
SK (1) | SK282833B6 (de) |
WO (1) | WO1997019068A1 (de) |
ZA (1) | ZA969584B (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
ES2195034T3 (es) * | 1995-12-08 | 2003-12-01 | Agouron Pharma | Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion. |
US6747027B1 (en) * | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US6624177B1 (en) | 1996-09-04 | 2003-09-23 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
KR20000068414A (ko) * | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도 |
AU736347B2 (en) | 1996-09-04 | 2001-07-26 | Warner-Lambert Company | Compounds for and a method of inhibiting matrix metalloproteinases |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
KR20000057444A (ko) * | 1996-12-09 | 2000-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 심기능부전 및 심실확장의 치료 및 예방 방법 |
EP1366765A1 (de) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | VerWendung von Matrix-Metalloproteinase Inhibitoren zur Behandlung von neurologischen Erkrankungen und zur Förderung der Wundheilung |
CA2264692A1 (en) * | 1996-12-17 | 1998-06-25 | Warner-Lambert Company | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
TR200101905T2 (tr) | 1997-04-28 | 2002-06-21 | Texas Biotechnology Corporation | Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler. |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
PT877019E (pt) * | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
CA2318145C (en) | 1998-02-04 | 2009-10-27 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
WO2000015213A1 (fr) * | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Agent de prevention ou de traitement de l'insuffisance cardiaque congestive |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
CA2464727A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
PT1465861E (pt) * | 2001-12-20 | 2009-07-08 | Bristol Myers Squibb Co | Derivados de α-(n-sulfonamido)-acetamida como inibidores β-amilóides |
US6864478B2 (en) * | 2002-04-22 | 2005-03-08 | Visx, Incorporation | Beam position monitoring for laser eye surgery |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
US7537774B2 (en) * | 2005-12-23 | 2009-05-26 | Orion Therapeautics, Llc | Therapeutic formulation |
US20090069304A1 (en) * | 2006-03-03 | 2009-03-12 | Shionogi & Co., Ltd. | Mmp-13 selective inhibitor |
EP2128134A1 (de) * | 2006-11-02 | 2009-12-02 | Shionogi&Co., Ltd. | Zur selektiven inhibierung von mmp-13 fähige sulfonylharnstoffderivate |
US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
WO2009137657A1 (en) * | 2008-05-08 | 2009-11-12 | Bristol-Myers Squibb Company | 2-aryl glycinamide derivatives |
US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
US7977362B2 (en) * | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
US20110071199A1 (en) * | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100158A3 (de) * | 1982-07-28 | 1985-03-27 | The Upjohn Company | (3-Pyridinyl)-heteroalkarylalkanole, ihre Alkansäuren und ihre Ester |
DE3330603A1 (de) * | 1983-08-25 | 1985-03-21 | Hoechst Ag, 6230 Frankfurt | Neue 2-amino-alkenylsulfonylharnstoffe |
GB8609630D0 (en) * | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
EP0673247A4 (de) * | 1992-12-01 | 1996-05-01 | Merck & Co Inc | Fibrinogen rezeptor antagonisten. |
CA2110524A1 (en) * | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL109144A (en) * | 1993-03-29 | 2000-02-29 | Zeneca Ltd | Glycoprotein IIB/IIIA inhibiting 4-pyridylamino heterocyclic derivatives process for their preparation and pharmaceutical compositions containing them |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
CN1049651C (zh) * | 1994-01-20 | 2000-02-23 | 英国生物技术药物有限公司 | 金属蛋白酶抑制剂 |
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
US5919940A (en) * | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
KR20000057444A (ko) * | 1996-12-09 | 2000-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 심기능부전 및 심실확장의 치료 및 예방 방법 |
CA2264692A1 (en) * | 1996-12-17 | 1998-06-25 | Warner-Lambert Company | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
-
1996
- 1996-10-18 AU AU74641/96A patent/AU727569B2/en not_active Ceased
- 1996-10-18 NZ NZ321293A patent/NZ321293A/en unknown
- 1996-10-18 ES ES96936718T patent/ES2184893T3/es not_active Expired - Lifetime
- 1996-10-18 DE DE69624262T patent/DE69624262T2/de not_active Expired - Fee Related
- 1996-10-18 PT PT96936718T patent/PT874836E/pt unknown
- 1996-10-18 JP JP09519715A patent/JP2000514779A/ja not_active Abandoned
- 1996-10-18 PL PL96326700A patent/PL326700A1/xx unknown
- 1996-10-18 DK DK96936718T patent/DK0874836T3/da active
- 1996-10-18 SK SK641-98A patent/SK282833B6/sk unknown
- 1996-10-18 CZ CZ19981467A patent/CZ291659B6/cs not_active IP Right Cessation
- 1996-10-18 WO PCT/US1996/016761 patent/WO1997019068A1/en active IP Right Grant
- 1996-10-18 HU HU9902083A patent/HUP9902083A3/hu unknown
- 1996-10-18 EP EP96936718A patent/EP0874836B1/de not_active Expired - Lifetime
- 1996-10-18 IL IL12390196A patent/IL123901A/xx not_active IP Right Cessation
- 1996-10-18 AT AT96936718T patent/ATE225779T1/de not_active IP Right Cessation
- 1996-10-18 BR BR9611487A patent/BR9611487A/pt not_active IP Right Cessation
- 1996-10-18 US US09/068,726 patent/US5977141A/en not_active Expired - Fee Related
- 1996-11-14 ZA ZA969584A patent/ZA969584B/xx unknown
-
1998
- 1998-05-13 BG BG102448A patent/BG63967B1/bg unknown
- 1998-05-15 NO NO19982223A patent/NO310231B1/no not_active IP Right Cessation
-
1999
- 1999-10-05 US US09/412,707 patent/US6153612A/en not_active Expired - Fee Related
-
2000
- 2000-06-22 US US09/599,306 patent/US6297247B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUP9902083A3 (en) | 2000-06-28 |
HUP9902083A2 (hu) | 1999-10-28 |
DE69624262T2 (de) | 2003-09-11 |
NO982223L (no) | 1998-05-15 |
CZ146798A3 (cs) | 1998-08-12 |
SK282833B6 (sk) | 2002-12-03 |
ZA969584B (en) | 1997-06-02 |
US6297247B1 (en) | 2001-10-02 |
SK64198A3 (en) | 1998-10-07 |
BR9611487A (pt) | 1999-01-19 |
JP2000514779A (ja) | 2000-11-07 |
EP0874836B1 (de) | 2002-10-09 |
ES2184893T3 (es) | 2003-04-16 |
WO1997019068A1 (en) | 1997-05-29 |
NZ321293A (en) | 2001-04-27 |
AU7464196A (en) | 1997-06-11 |
NO310231B1 (no) | 2001-06-11 |
AU727569B2 (en) | 2000-12-14 |
IL123901A (en) | 2003-06-24 |
US6153612A (en) | 2000-11-28 |
DE69624262D1 (de) | 2002-11-14 |
BG63967B1 (bg) | 2003-08-29 |
PL326700A1 (en) | 1998-10-26 |
BG102448A (en) | 1999-08-31 |
CZ291659B6 (cs) | 2003-04-16 |
US5977141A (en) | 1999-11-02 |
IL123901A0 (en) | 1998-10-30 |
NO982223D0 (no) | 1998-05-15 |
DK0874836T3 (da) | 2003-02-10 |
EP0874836A1 (de) | 1998-11-04 |
PT874836E (pt) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE225779T1 (de) | Sulfonamidinhibitoren von matrix metalloproteinasen | |
NZ509439A (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | |
ATE182137T1 (de) | Peptidylderivate als inhibitoren von metalloproteinase | |
PT876343E (pt) | Ceto-acidos aromaticos e seus derivados como inibidores metaloproteinases de matriz | |
DE69427582T2 (de) | Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten | |
DE69131044T2 (de) | Interleukin-i antagonist und seine verwendung | |
BR9712794A (pt) | Compostos para e um método de inibição de metaloproteinases matriciais | |
DK0828726T3 (da) | Tricykliske inhibitorer af matrixmetalloproteinaser | |
DE69533876D1 (de) | Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen. | |
ATE167690T1 (de) | Polyetheramidoamine hydrogele als heparinersatz | |
CA2233560A1 (en) | Sulfonamide inhibitors of matrix metalloproteinases | |
DE69623325T2 (de) | 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus | |
ID20165A (id) | Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis | |
UY24693A1 (es) | Ácidos bifenil butíricos y sus derivados como inhibidores de metaloproteinasas de matriz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0874836 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |